Non‐pulmonary CFTR‐related symptom improvement with ivacaftor in p.Phe508del/p.Arg117His (7T) cystic fibrosis
Abstract Diagnosis and management of CRMS/CFSPID and cystic fibrosis (CF) with mild phenotypes remains challenging, and this extends to expanding practice with the use of CFTR modulators. We describe a case of an 18‐year‐old man with p.F508del/p.Arg117His(7T) initially presenting with CRMS/CFSPID. H...
Main Authors: | Stephanie L. Kuek, R. John H. Massie |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-01-01
|
Series: | Respirology Case Reports |
Subjects: | |
Online Access: | https://doi.org/10.1002/rcr2.1079 |
Similar Items
-
Post-approval studies with the CFTR modulators Elexacaftor-Tezacaftor—Ivacaftor
by: Burkhard Tümmler, et al.
Published: (2023-03-01) -
Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor Therapy in Three Subjects with the Cystic Fibrosis Genotype Phe508del/Unknown and Advanced Lung Disease
by: Vito Terlizzi, et al.
Published: (2021-07-01) -
Efficacy and Safety of Elexacaftor-Tezacaftor-Ivacaftor in the Treatment of Cystic Fibrosis: A Systematic Review
by: Nikoletta Kapouni, et al.
Published: (2023-03-01) -
Editorial: Real-world experience with CFTR modulator therapy
by: Burkhard Tümmler, et al.
Published: (2023-11-01) -
Elexacaftor Mediates the Rescue of F508del CFTR Functional Expression Interacting with MSD2
by: Roberta Bongiorno, et al.
Published: (2023-08-01)